KRMD · KORU Medical Systems, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on KRMD. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About KRMD · KORU Medical Systems, Inc.
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
Live Quote
HOLD (score +0) · 12-1 mom 16.3% · RSI 55.3 · above_50_only · -36.7% from high
Targets blend Wall Street consensus (5 analysts: low $5.00 / mean $6.80 / high $8.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
KRMD presents a mixed picture: Q1 2026 was a record revenue quarter (+22% YoY) driven by domestic SCIg share gains and accelerating international growth tied to prefilled syringe conversions in EU. A CEO transition is scheduled for July 1 with COO Adam Kalbermatten (incoming CEO) receiving substantial equity grants that vest on multi-year performance conditions — an alignment signal but also a dilution overhang. The CFO and COO both made open-market purchases of ~$19-21K each in mid-May, weeks before the next earnings report. EU MDR certification for Freedom60 was secured in March 2026, opening broader European access. However, KRMD trades at ~48x forward P/E with negative GAAP net income (loss-making TTM), below both its 50-DMA and 200-DMA, RSI neutral zone at 41, no whale options positioning detected, and a customer concentration risk (one distributor = ~29% of revenues; nine distributors = ~77%). No analyst downgrades or earnings misses in recent history. The small-cap medical device name lacks sufficient liquidity for robust option strategies.